My Treatment Approach: Metastatic Triple-Negative Breast Cancer

Expert oncologists share insight on the prognosis of triple-negative breast cancer (TNBC) and broadly review current treatment options for patients.

After reviewing a patient scenario of relapsed/refractory metastatic TNBC, expert oncologists elucidate use of sacituzumab govitecan in this setting.

Comprehensive discussion on the safety and efficacy profile of the antibody-drug conjugate (ADC) sacituzumab govitecan and managing ADC-related adverse events in patients with mTNBC.

Expert oncologists review novel ADCs in TNBC and consider how their approval may impact sequencing of therapy in this setting.

Perspectives on the most prominent unmet needs in metastatic triple-negative breast cancer and how these may be addressed with future clinical trials.

Before closing out their conversation on metastatic triple-negative breast cancer, expert oncologists share a few clinical pearls on optimizing TNBC management.